How a rare drug made from scientists’ blood saves babies from botulism

An infant botulism outbreak has sickened at least 39 babies across the U.S., underscoring the crucial role of a medication that treats the rare disease.

Is the CSL share price a generational bargain at $180?

CSL shares have come under pressure recently. Is this one of those rare moments when a top-tier blue chip becomes a genuine ...

Here's the earnings forecast out to 2030 for CSL shares

CSL Ltd (ASX:CSL) shares have benefited from strong profit growth. Let’s take a look at what analysts believe could happen ...

2 big ASX 200 shares this fund manager rates as buys

These large businesses could be strong contenders for returns. The post 2 big ASX 200 shares this fund manager rates as buys ...
Road & Track

Now Is Your Chance to Own the World's First BMW M Car

BMW’s M Division is responsible for some of the most legendary enthusiast cars ever put to pavement. And while the titular M1 was the motorsport division’s first serialized road car, it was not the ...
Pharmaceutical Technology

CSL to pump $1.5bn into US plasma supply chain

CSL Behring, the CSL’s plasma business, generated $11.16bn in revenue in 2024. Credit: ArDanMe via Shutterstock.com. CSL will outlay $1.5bn over the next five years in the US to grow its footprint of ...
The Australian Financial Review

CSL plans $2.3b US manufacturing plant as Trump tariffs loom

CSL will invest $2.3 billion to expand its North American manufacturing facilities over the next five years, joining other global pharmaceutical companies seeking exemptions from US President Donald ...
Reuters

Australia's CSL plans to invest $1.5 billion in US plasma therapy expansion

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...
Seeking Alpha

Australian biotech CSL announces $1.5B investment in the U.S.

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...
FiercePharma

CSL charts US plasma manufacturing expansion with $1.5B investment

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
The Australian Financial Review

Falling US vaccine rates have hit CSL. They might help it recover, too

Gift 5 articles to anyone you choose each month when you subscribe. Global biotech CSL says its US vaccines business will recover in the medium term when falling immunisation rates trigger a severe ...
Bloomberg L.P.

CSL Predicts US Flu-Shot Rebound as Seqirus Expands in Europe

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...